Non-alcoholic SteatohepatitisPhase 3ESSENCENCT04822181
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
A Phase 3 study testing Semaglutide in people with Non-alcoholic Steatohepatitis, run by Novo Nordisk A/S at 558 sites in 39 countries.
Trial summary
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-alcoholic Steatohepatitis
- What is being tested?
- Semaglutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,205 participants
- Where
- 558 sitesin 39 countries
- Study dates
- 1 Apr 2021to 25 Apr 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age above or equal to 18 years at the time of signing informed consent.
- Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1).
- Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy.
- A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy.
Who cannot join
- Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)
- Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
- Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.
- Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
- Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.
- Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).
- Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.
Trial locations and contacts
558 sites in 39 countries.
558 sites in 39 countries
United States130 sites
Amarillo Center for Clinical Research, Ltd.
Amarillo, Texas, 79106
University of Michigan Medicine
Ann Arbor, Michigan, 48109
Texas Clin Res Inst, LLC
Arlington, Texas, 76012
Emory University Hospital
Atlanta, Georgia, 30322-1059
Mercy Medical Center, GI Research
Baltimore, Maryland, 21202
Walter Reed Nat Mil Md Ctr
Bethesda, Maryland, 20889
Boston Medical Center_Cary
Boston, Massachusetts, 02118
Encore Medical Research of Boynton Beach LLC
Boynton Beach, Florida, 33436
The Institute for Liver Health
Chandler, Arizona, 85224
Medical University Of South Carolina
Charleston, South Carolina, 29425
AtriumHealth Liver Care, Pineville
Charlotte, North Carolina, 28210
University Of Virginia Hospital
Charlottesville, Virginia, 22908
WR-ClinSearch, LLC
Chattanooga, Tennessee, 37421
Clinical Research Professionals
Chesterfield, Missouri, 63005
Rush University Med. Cntr
Chicago, Illinois, 60612
University Of Chicago
Chicago, Illinois, 60637
Iowa Digestive Disease Center
Clive, Iowa, 50325
Peak Gastro Assoc-Col Springs
Colorado Springs, Colorado, 80907
Columbus Regional Research Institute
Columbus, Georgia, 31904
Ohio State Univ Wexner Med Ctr
Columbus, Ohio, 43210
Northeast GI Research Division
Concord, North Carolina, 28027
Clinical Res Collaborative
Cumberland, Rhode Island, 02864
Liver Ins@ Mthdist DTX Med Cen
Dallas, Texas, 75203
Velocity Clinical Res-Dallas
Dallas, Texas, 75230
UT Southwestern Med Cntr
Dallas, Texas, 75390-9302
Geisinger Clinic
Danville, Pennsylvania, 17822
Henry Ford Health System
Detroit, Michigan, 48202
Integrity Clinical Research, LLC
Doral, Florida, 33122
Duke Univ. Med CNTR_Durham_2
Durham, North Carolina, 27710
South Texas Research Institute
Edinburg, Texas, 78539
Gastroenterology & Liver Institute
Escondido, California, 92025
Inova Fairfax Medical Campus
Falls Church, Virginia, 22042
AIG Digestive Disease Research
Florham Park, New Jersey, 07932
Covenant Metabolic Specialists, Ft. Myers
Fort Myers, Florida, 33912
Brooke Army Medical Ctr.
Fort Sam Houston, Texas, 78234
GI Alliance Research
Fort Worth, Texas, 76104
University of Florida-CTRB
Gainesville, Florida, 32610
Woodholme Gastroenterology Associates
Glen Burnie, Maryland, 21061
Shang Wu M.D. Inc.
Hacienda Heights, California, 91745
Digestive Health Res-TSMC
Hermitage, Tennessee, 37076
Pennsylvania State University
Hershey, Pennsylvania, 17033
Miguel Rebollar PA
Hialeah, Florida, 33012
Direct Helpers Research Center
Hialeah, Florida, 33016
Tandem Clinical Research - Houma
Houma, Louisiana, 70363
Bylr Coll Md-Ben Taub Gen Hos
Houston, Texas, 77030-1608
Baylor College Of Medicine
Houston, Texas, 77030
Houston Methodist Hospital
Houston, Texas, 77030
Bipharma Informatic Inc.
Houston, Texas, 77043
Houston Research Institute
Houston, Texas, 77079
Biopharma Informatic
Houston, Texas, 77084
Amir Ali Hassan, MD, PA
Houston, Texas, 77089
North AL Health Res, LLC
Huntsville, Alabama, 35801
Indiana University Hospital
Indianapolis, Indiana, 46202
Southern Therapy and Advanced Research LLC
Jackson, Mississippi, 39216
East Tennessee Research Institute
Johnson City, Tennessee, 37604
ARcare Center for Clinical Research
Jonesboro, Arkansas, 72401
University Of Kansas Hospital
Kansas City, Kansas, 66160
Kansas City Research Institute
Kansas City, Missouri, 64131
Scripps Whittier Diabetes Inst
La Jolla, California, 92037
UCSD NAFLD Research Center
La Jolla, California, 92037
Florida Research Institute, LLC
Lakewood Rch, Florida, 34211-4930
OM Research LLC
Lancaster, California, 93534
Jubilee Clinical Research, Inc.
Las Vegas, Nevada, 89106
Sierra Clinical Research-Las Vegas
Las Vegas, Nevada, 89106
Ocean St Clin Res Partnrs, LLC
Lincoln, Rhode Island, 02865
ARcare Center for Clinical Research
Little Rock, Arkansas, 72205
Arkansas Diagnostic Center, PA
Little Rock, Arkansas, 72205
Digestive Hlth Res of SoCa
Long Beach, California, 90808
Gastroenterology Assoc_ CGA
Macon, Georgia, 31201
Sandhill Research, LLC
Maitland, Florida, 32751
Tandem Clinical Research - Maitland
Maitland, Florida, 32751
Gastroint Spec of Georgia
Marietta, Georgia, 30060
Tandem Clinical Research
Marrero, Louisiana, 70072
Centex Studies - McAllen
McAllen, Texas, 78504
Tandem Clinical Research - Metairie
Metairie, Louisiana, 70006
Optimus U, Corp
Miami, Florida, 33135
Univ of Miami/Schiff Ctr
Miami, Florida, 33136
Genoma Research Group, Inc
Miami, Florida, 33173
IMIC Inc
Miami, Florida, 33176
San Marcus Res Clin Miami Lakes
Miami Lakes, Florida, 33014
Quality Medical Research
Nashville, Tennessee, 37211
Yale Ctr for Clin Invest
New Haven, Connecticut, 06519
NYU Grossman School of Med
New York, New York, 10016
Weill Cornell Med Coll-NYPH
New York, New York, 10021
Icahn Sch of Med-Mt Sinai Hosp
New York, New York, 10029
Digestive and Liver Disease Specialists
Norfolk, Virginia, 23502
Ocala GI Research
Ocala, Florida, 34471
Sensible Healthcare LLC
Ocoee, Florida, 34761
South Ogden Family Medicine/ CCT Research
Ogden, Utah, 84405
Univ of Nebraska Medical CTR
Omaha, Nebraska, 68198-3020
OM Research LLC
Oxnard, California, 93030
Cedars-Sinai Medical Center
Pasadena, California, 90048
Pasedena Liver Center
Pasadena, California, 91105
LinQ Research, LLC
Pearland, Texas, 77584
Inst-Liver Hlth dba AZ Liver H
Peoria, Arizona, 85381
Univ of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107-5244
UPMC Center for Liver Diseases
Pittsburgh, Pennsylvania, 15213
UPMC_Center for Liver Care
Pittsburgh, Pennsylvania, 15213
Care Access Research, Pottsville
Pottsville, Pennsylvania, 17901
Inland Empire Clin Trials LLC
Rialto, California, 92377
Bon Secours Richmond Community Hospital LLC
Richmond, Virginia, 23226
McGuire VA Medical Center
Richmond, Virginia, 23249
VCU Health System
Richmond, Virginia, 23298
Velocity Clinical Research, Riverton
Riverton, Utah, 84065
Gastroent Consult of SW VA
Roanoke, Virginia, 24014
Mayo Clinic
Rochester, Minnesota, 55905-0001
UC Davis Hlth -Midtwn Ambu Cen
Sacramento, California, 95817
University of Utah
Salt Lake City, Utah, 84132
Amer. Rrsch Corp-TX Liver Inst
San Antonio, Texas, 78215
Clinical Trials of Texas, LLC
San Antonio, Texas, 78229
University of California, San Francisco
San Francisco, California, 94143
San Jose Gastroenterology
San Jose, California, 95116
Covenant Metabolic Specialists LLC
Sarasota, Florida, 34240
Headlands Research - Sarasota
Sarasota, Florida, 34243
Louisiana Research Center, LLC
Shreveport, Louisiana, 71105
Endeavor Health
Skokie, Illinois, 60077
Digestive Research Alliance of Michiana
South Bend, Indiana, 46635
Premier Health Research, LLC
Sparta, New Jersey, 07871
Objective GI
Springboro, Ohio, 45066
Theia Clinical Research Centers LLC
St. Petersburg, Florida, 33710
Mt Olympus Medical Research, LLC
Sugar Land, Texas, 77479
Kansas Medical Clinic, PA
Topeka, Kansas, 66606
Inst. Liver H II dba AZ Liver H
Tucson, Arizona, 85712
Del Sol Research Management, LLC
Tucson, Arizona, 85715
Options Health Research, LLC
Tulsa, Oklahoma, 74104
ClinCloud, LLC
Viera E., Florida, 32940
CRIOH
Westlake, Ohio, 44145
Digestive Hlth Res of N Texas
Wichita Falls, Texas, 76301
Florida Medical Clinic Orlando Health
Zephyrhills, Florida, 33542
Japan59 sites
Juntendo University Hospital, Gastroenterology
Bunkyo-ku, Tokyo, 113-8431
Juntendo University Hospital_Gastroenterology
Bunkyo-ku, Tokyo, 113-8431
The University of Tokyo Hospital, Gastroenterology
Bunkyo-ku, Tokyo, 113-8655
Fukui-ken Saiseikai Hospital, Internal Medicine
Fukui-shi, Fukui, 918-8503
Fukui-ken Saiseikai Hospital_Internal Medicine
Fukui-shi, Fukui, 918-8503
Hoshi General Hospital_Gastroenterology
Fukushima, 963-8801
Gifu Municipal Hospital_Hepatology
Gifu, 500-8513
Ogaki Municipal Hospital_Gastroenterology and Hepatology
Gifu, 503-8502
Hamamatsu University Hospital_Liver Internal Medicine
Hamamatsu-shi, Shizuoka, 431-3192
JA Hiroshima General Hospital_Gastroenterology and Hepatology
Hatsukaichi-shi, Hiroshima, 783-8503
Hiroshima Red Cross & Atomic-b_Hepatology
Hiroshima-shi, Hiroshima, 730-8619
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hosp.
Hiroshima-shi, Hiroshima, 730-8619
Hiroshima University Hospital_Department of Gastro.&Metabo.
Hiroshima-shi, Hiroshima, 734-8551
Hiroshima University Hospital
Hiroshima-shi, Hiroshima, 734-8551
Juntendo University Shizuoka Hospital_Gastroenterology & Hepatology
Izunokuni-shi, Shizuoka, 410-2295
Juntendo University Shizuoka Hospital
Izunokuni-shi, Shizuoka, 410-2295
Kagoshima University Hospital, Gastroenterology
Kagoshima-shi, Kagoshima, 890-8520
Kagoshima University Hospital_Gastroenterology
Kagoshima-shi, Kagoshima, 890-8520
University Hospital Kyoto Prefectual University of Medicine
Kamigyo-ku, Kyoto, 602-8566
Kanazawa University Hospital_Gastroenterology
Kanazawa-shi, Ishikawa, 920-8641
Kanazawa University Hospital
Kanazawa-shi, Ishikawa, 920-8641
Nara Medical University Hospital_Department of Gastro.& Metabo.
Kashihara-shi, Nara, 634-8522
Nara Medical University Hospital_Kashihara-shi, Nara
Kashihara-shi, Nara, 634-8522
St. Marianna University School of Medicine Hospital_Division of Gastro.&Hepato.
Kawasaki-shi, Kanagawa, 216-8511
St. Marianna University School of Medicine Hospital
Kawasaki-shi, Kanagawa, 216-8511
Kumamoto Shinto General Hospital_Liver・Gastroenterology
Kumamoto-shi, Kumamoto, 862-8655
Toranomon Hospital, Hepatology
Minato-ku, Tokyo, 105-8470
Japanese Red Cross Musashino Hospital_Gastroenterology
Musashino-shi, Tokyo, 180-8610
Japanese Red Cross Musashino Hospital
Musashino-shi, Tokyo, 180-8610
Aichi Medical University Hospital_Hepatology and pancreology
Nagakute-shi, Aichi, 480-1195
Aichi Medical University Hospital
Nagakute-shi, Aichi, 480-1195
Heartlife Hospital_Liver internal medicine
Nakagamigun, Okinawa, 901-2492
Nara City Hospital, Gastroenterology and Hepatology
Nara-shi, Nara, 630-8305
Hyogo Medical University Hospital_Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine
Nishinomiya-shi, Hyogo, 663-8501
Oita Cardiovascular Hospital_Gastroenterology
Oita-shi, Oita, 870-0837
Kawasaki Medical School General Medical Center_Internal Medicine
Okayama-shi, Okayama, 700-8505
Kawasaki Medical School General Medical Center
Okayama-shi, Okayama, 700-8505
Japan Organization of Occupational Health and Safety Osaka Rosai Hospital_Gastroenterology
Osaka, 591-8025
Osaka Metropolitan University Hospital, Department of Hepatology
Osaka-shi, Osaka, 545-8586
Osaka Metropolitan University Hospital_Department of Hepatology
Osaka-shi, Osaka, 545-8586
Otsu City Hospital, Gastroenterological Medicine
Otsu-shi, Shiga, 520-0804
Saga University Hospital_Liver Center
Saga-shi, Saga, 849-8501
Japan Community Health care Organization Hokkaido Hospital
Sapporo-shi, Hokkaido, 062-8618
JCHO Hokkaido Hospital_Digestive Disease Center
Sapporo-shi, Hokkaido, 062-8618
Sendai Kousei Hospital_Liver Internal Medicine
Sendai-shi, Miyagi, 981-0914
Sendai Kousei Hospital
Sendai-shi, Miyagi, 981-0914
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, 162-8666
Saiseikai Suita Hospital, Gastroenterology
Suita-shi, Osaka, 564-0013
Osaka University Hospital_Department of Gastro. & Hepato
Suita-shi, Osaka, 565-0871
Kagawa Prefectural Central Hospital_Liver internal medicine
Takamatsu-shi, Kagawa, 760-8557
Kagawa Prefectural Central Hospital
Takamatsu-shi, Kagawa, 760-8557
National Hospital Organization Takasaki General Medical Ctr._Gastroenterology
Takasaki-shi, Gunma, 370-0829
Nihon University Itabashi Hospital_Division of Gastro.&Hepa.
Tokyo, 173-8610
Nihon University Itabashi Hospital
Tokyo, 173-8610
Ehime University Hospital_Department of Gastro.& Metabo.
Toon-shi, Ehime, 791-0295
Ehime University Hospital
Toon-shi, Ehime, 791-0295
Saiseikai Wakayama Hospital_Gastroenterology
Wakayama-shi, Wakayama, 640-8158
Saiseikai Wakayama Hospital
Wakayama-shi, Wakayama, 640-8158
Yokohama City University Hospital_Gastrointestinal Medicine
Yokohama-shi, Kanagawa, 236-0004
China41 sites
Beijing Ditan Hospital Capital Medical University-Hepatology
Beijing, Beijing Municipality, 100015
Peking University People's Hospital-(White Pagoda Temple Area) - Hepatopathy
Beijing, Beijing Municipality, 100034
Beijing Friendship Hospital, Capital Medical University-Endocrinology
Beijing, Beijing Municipality, 100050
Beijing You'an Hospital, Capital Medical University-Hepatology center
Beijing, Beijing Municipality, 100069
Beijing Tsinghua Changgung Hospital-Hepatology
Beijing, Beijing Municipality, 102218
The First Bethune Hospital of Jilin University-Hepatic Biliary Pancreatic Medicine
Changchun, Jilin, 130021
Hunan Provincial People's Hospital-Hepatology
Changsha, Hunan, 410005
Hunan Provincial People's Hospital
Changsha, Hunan, 410005
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, 213003
West China Hospital Sichuan University-Infectious Diseases
Chengdu, Sichuan, 610044
Chongqing University Three Gorges Hospital-Hepatology
Chongqing, Chongqing Municipality, 404140
The First People's Hospital of Foshan-Infectious Disease
Foshan, Guangdong, 528000
Guangzhou Eighth People's Hospital, Guangzhou Medical University-Hepatology
Guangzhou, Guangdong, 510060
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080
Guangzhou First People's Hospital-Gastroenterology
Guangzhou, Guangdong, 510180
Nanfang Hospital, Southern Medical University-Infectious Diseases
Guangzhou, Guangdong, 510515
The Third Affiliated Hospital, Sun Yat-sen University-Infectious
Guangzhou, Guangdong, 510650
Zhejiang Hospital-Infectious Diseases
Hangzhou, Zhejiang, 310030
Zhejiang Hospital-Infectious Diseases
Hangzhou, 310030
Jinan Central Hospital
Jinan, Shandong, 250013
Liaocheng People's Hospital-Infectious Diseases
Liaocheng, Shandong, 252000
Liaocheng People's Hospital
Liaocheng, Shandong, 252000
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
The Second Affiliated Hospital of Nanjing Medical University-Hepatology
Nanjing, Jiangsu, 210003
Qingdao Municipal Hospital (Group)-Infectious Diseases
Qingdao, Shandong, 266011
Shanghai Jiao Tong University School of Medicine Renji Hospital-Gastroenterology
Shanghai, Shanghai Municipality, 200001
Ruijin Hospital Affiliate to The Shanghai Jiaotong University-Infectious Diseases
Shanghai, Shanghai Municipality, 200025
Ruijin Hospital Affiliate to The Shanghai Jiaotong Universit
Shanghai, Shanghai Municipality, 200025
Shanghai Ninth People's Hospital-Infection Disease
Shanghai, Shanghai Municipality, 201999
Shanghai Ninth People's Hospital
Shanghai, Shanghai Municipality, 201999
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036
The Third People's Hospital of Shenzhen-Hepatology
Shenzhen, Guangdong, 518112
The Third People's Hospital of Shenzhen
Shenzhen, 518112
The Third Hospital of Hebei Medical University-Hepatology
Shijiazhuang, Hebei, 050051
Tianjin Third Central Hospital-Gastroenterology
Tianjin, Tianjin Municipality, 300170
Tianjin Second People's Hospital-Liver Disease Department III
Tianjin, Tianjin Municipality, 300211
Tianjin Second People's Hospital-Liver Disease Department III
Tianjin, 300211
The First Affiliated Hospital of WMU
Wenzhou, Zhejiang, 325000
The Affiliated Hospital of Xuzhou Medical University (East) - Infectious Diseases
Xuzhou, Jiangsu, 221011
General Hosp of Ningxia Medical University,Infectious Depart
Yinchuan, Ningxia, 750004
The Third People's Hospital of Zhenjiang-Hepatology
Zhenjiang, Jiangsu, 212021
United Kingdom26 sites
Royal Victoria Hospital
Belfast, BT12 6BA
Queen Elizabeth Hospital, Birmingham
Birmingham, B15 2TH
University Hospital Coventry - WISDEM Centre
Coventry, CV2 2DX
Royal Derby Hospital
Derby, DE22 3DT
Royal Derby Hospital
Derby, DE22 3NE
Ninewells Hospital
Dundee, DD1 9SY
Royal Devon and Exeter Hospital
Exeter, EX2 5DW
Hull Royal Infirmary_Hull
Hull, HU3 2GZ
Hull Royal Infirmary
Hull, HU3 2GZ
Ipswich Hospital - Diabetes
Ipswich, IP4 5PD
The Diabetes Centre
Ipswich, IP4 5RH
St James's University Hospital
Leeds, LS9 7TF
St. James University Hospital
Leeds, LS9 7TF
The Royal London Hospital - Grahame Hayton Unit
London, E1 1FR
Royal Free Hospital - Immunity & Transplantation
London, NW3 2QG
Institute of Liver Studies
London, SE5 9RS
Chelsea & Westminster Hospital
London, SW10 9NH
Imperial College London
London, W2 1NY
Freeman Hospital, Newcastle
Newcastle upon Tyne, NE7 7DN
Nottingham University Hospitals NHS Trust
Nottingham, NG7 2UH
Nottingham University Hospital
Nottingham, NG7 2UH
John Radcliffe Hospital
Oxford, OX3 9DU
Derriford Hospital - Plymouth
Plymouth, PL6 8DH
Northern General Hospital
Sheffield, S5 7AU
Southampton General Hospital
Southampton, SO16 6YD
Joint Clinical Research Facility - Swansea
Swansea, SA2 8PP
India19 sites
Post Graduate Institute of Medical Education & Research_Chandigarh
Chandigarh, Punjab, 160012
All India Institute of medical Sciences
Delhi, New Delhi, 110029
Institute of liver and Biliary Sciences
Ghitorni, New Delhi, 110070
Medanta - The Medicity Multi-Speciality Hospital, Gurugram
Gurgaon, Haryana, 122001
Osmania General Hospital_Hyderabad
Hyderabad, Telangana, 500012
Dr P V Rao - Diabetes Research Centre
Hyderabad, Telangana, 50082
S.R.Kalla Memorial Gastro & General Hospital
Jaipur, Rajasthan, 302001
SMS Super speciality Hospital, Department of Gastroenterology
Jaipur, Rajasthan, 302004
MV Hospital and Research Centre
Lucknow, Uttar Pradesh, 226003
Dayanand Medical College & Hospital
Ludhiana, Punjab, 141001
Kasturba Medical College Hospitals (KMC Hospitals), Mangalore
Mangalore, Karnataka, 575001
Fortis Heart Institute and Multispeciality Hospital
Mohali, Punjab, 160062
Gleneagles Hospital, Super-speciality and Transplant Centre, Parel
Mumbai, Maharashtra, 400012
Seth GS medical college and KEM Hospital
Mumbai, Maharashtra, 400012
Midas Multispeciality Hospital
Nagpur, Maharashtra, 441108
Fortis Escort Heart Institute
New Delhi, 110025
Yashoda Hospital
Secunderabad, Andhra Pradesh, 500003
Surat Institute of Digestive Science
Surat, Gujarat, 395002
BAPS Pramukh Swami Hospital
Surat, Gujarat, 395009
Turkey (Türkiye)18 sites
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
Adana, 01000
Hacettepe Universitesi Tıp Fakültesi- Gastroenteroloji
Ankara, 06230
Ankara Universitesi Tıp Fakultesi Gastroenteroloji Bilim Da
Ankara, 06590
Ankara Üniversitesi Tıp Fakültesi Cebeci Araştırma Ve Uygulama Hastanesi-Gastroenteroloji
Ankara, 06590
Ankara Bilkent Şehir Hastanesi-Gastroenteroloji
Ankara, 06800
Ankara Sehir Hastanesi,Gastroenteroloji Klinigi
Ankara, 06800
Bursa Uludağ Üniversitesi Hastanesi-Gastroenteroloji
Bursa, 16059
Uludag Universitesi Tıp Fakultesi-Gastroenteroloji
Bursa, 16059
Koc Universitesi Hastanesi-Gastroenteroloji
Istanbul, 34010
Bezmialem Vakıf Üniversitesi Hastanesi-Gastroenteroloji
Istanbul, 34093
Istanbul Universitesi Istanbul Tip Fakultesi-Gastroenterolog
Istanbul, 34093
Umraniye Egitim ve Arastirma Hastanesi, Gastroenteroloji
Istanbul, 34764
Marmara Üniversitesi Pendik EAH- Gastroenteroloji
Istanbul, 34899
Ege Universitesi Tip Fakultesi Hastanesi, Gastroenteroloji
Izmir, 35100
Kocaeli Üniversitesi Hastanesi - Gastroenteroloji
Kocaeli, 41000
Mersin Universitesi Tip Fakultesi Gastroenteroloji Bilim Dal
Mersin, 33343
Mersin Üniversitesi Tip Fakültesi Hastanesi -Gastroenteroloji
Mersin, 33343
Adana Şehir Eğitim ve Araştırma Hastanesi-Endokrinoloji
Yüreğir/Adana, 1370
Russia17 sites
Volosevich First City Clinical Hospital
Arkhangelsk, 163001
City Hospital #5
Barnaul, 656045
Kazan Federal University
Kazan', 420097
LLC "Clinic of Aesthetic Medicine & Laser Technologies"
Kazan', 420111
Friendship University of Russia
Moscow, 117292
Setchenov First Moscow State Medical University
Moscow, 119435
PHI "Central Clinical Hospital RZD- Medicine"
Moscow, 125367
Limited Law Company "Healthy Family" Medicine Center"
Novosibirsk, 630099
Penza Regional Clinical Hospital named after N.N. Burdenko
Penza, 440026
Joint Stock Company "Polyclinic Complex"
Saint Petersburg, 190013
SPb SBHI City Outpatient clinic #109
Saint Petersburg, 192283
Limited Liability Company "Energiya Zdoroviya"
Saint Petersburg, 194156
North-Western State Medical Univer. based on Med-Prof Center
Saint Petersburg, 195067
Consultative & Diagnostic Center with a Outpatient Hospital
Saint Petersburg, 197110
Siberian State Medical University
Tomsk, 634050
Ulianovsk Regional Clinical Hospital
Ulyanovsk, 432063
Polyclinic #2 in Yoshkar-Ola
Yoshkar-Ola, 424004
Bulgaria15 sites
MHAT - Uni Hospital OOD
Panagyurishte, 4500
MHAT Med Line Clinic
Plovdiv, 4000
"Acibadem City Clinic UMHAT Tokuda"
Sofia, 1407
Acibadem City Clinic UMHAT Tokuda EAD, Gastroenterology
Sofia, 1407
DCC Aleksandrovska EOOD
Sofia, 1431
UMHAT Sveti Ivan Rilski EAD, Gastroenterology
Sofia, 1431
Medical Center Vertebra OOD
Sofia, 1504
"UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Gastroenterology clinic
Sofia, 1527
UMHAT Tsaritsa Yoanna - ISUL EAD, Gastroenterology
Sofia, 1527
"DCC XX - Sofia" EOOD
Sofia, 1618
DCC XX - Sofia EOOD, Gastroenterology
Sofia, 1618
"UMHAT "Sveta Anna" Sofia" AD
Sofia, 1750
Acibadem City Clinic UMHAT EOOD, Gastroenterology
Sofia, 1784
Medical Center Synexus Sofia EOOD
Sofia, 1784
UMHAT Sveta Marina EAD, Clinic of Gastroenterology
Varna, 9010
Portugal15 sites
Hospital Garcia de Orta
Almada, 2805-267
ULS De Almada-Seixal E.P.E. - Hospital Garcia de Orta
Almada, 2805-267
ULS Da Regiao De Aveiro E.P.E. - Hospital Infante D. Pedro
Aveiro, 3814-501
ULS De Braga, E.P.E. - Hospital de Braga
Braga, 4710-243
ULS Da Guarda E.P.E. - Hospital Sousa Martins
Guarda, 6301-858
ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
Guimarães, 4835-044
APDP - Associação Protectora dos Diabéticos de Portugal
Lisbon, 1250-189
Unidade De Santa Maria E.P.E. - Hospital de Santa Maria
Lisbon, 1649-035
ULS De Santo António, E.P.E. - Hospital de Santo António
Porto, 4099-001
ULS De São João, E.P.E. - Hospital de São João
Porto, 4200-319
ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
Senhora Da Hora, Matosinhos, Matosinhos, 4464-513
ULS Do Alto Minho E.P.E. - Hospital de Santa Luzia
Viana do Castelo, 4904-858
Hospital da Luz Arrabida, S.A.
Vila Nova de Gaia, 4400-346
ULS De Gaia/Espinho E.P.E. - Hospital Eduardo Santos Silva
Vila Nova de Gaia, 4434-502
ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
Vila Real, 5000-508
Canada13 sites
LMC ClinRsrh Inc.Brampton
Brampton, Ontario, L6S 0C6
University of Calgary Liver Unit-(HMRC)
Calgary, Alberta, T2N 4Z6
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
Nova Scotia Hlth Halifax
Halifax, Nova Scotia, B3H 2Y9
London Hlth Sci Ctr- Univ Camp
London, Ontario, N6A 5A5
McGill University Health Centre
Montreal, Quebec, H4A 3J1
Clinique Medicine Urbaine du Quartier Latin, Inc.
Montreal, Quebec, QC H2L 4E9
Hospital Fleurimont / CIUSS
Sherbrooke, Quebec, J1H 5N4
Ctr de Med Metab de Lanaudiere
Terrebonne, Quebec, J6X 4P7
Centricity Research LMC (Toronto)
Toronto, Ontario, M4G 3E8
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
GI Research Inst Foundation
Vancouver, British Columbia, V6Z 2K5
TDDA Specialty Research
Vaughan, Ontario, L4L 4Y7
Germany13 sites
Gastro am Bayerischen Platz - Hofmann W.-P.n
Berlin, 10825
Charité - Campus Virchow-Klinikum - Med. Klinik für Hepatologie und Gastroenterologie
Berlin, 13353
Uniklinik Knappschaftskrankenhaus Bochum GmbH - Med. Klinik - Gastroenterologie & Hepatologie
Bochum, 44892
Universitätsklinikum Bonn - Med. Klinik und Poliklinik I
Bonn, 53127
Uniklinik FFM - Hepatologie
Frankfurt, 60590
Medizinische Hochschule Hannover - Gastroentero-, Hepato-, Endokrinologie
Hanover, 30625
Prof. Dr. Schiefke Ingolf, EUGASTRO GmbH
Leipzig, 04103
Universitätsklinikum Leipzig - Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie und Pneumologie
Leipzig, 04103
Uniklinik Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
Lübeck, 23538
Uniklinik Otto Von Guericke Magdeburg - Gastroenterologie, Hepatologie and Infektiologie
Magdeburg, 39120
Universitätsmedizin der JGU Mainz - Hepatologie
Mainz, 55131
Universitätsmedizin Mannheim - II. Medizinische Klinik
Mannheim, 68167
Universitätsklinikum Würzburg - Zentrum für Innere Medizin (ZIM)
Würzburg, 97080
Australia12 sites
Royal Adelaide Hospital - Hepatology Department
Adelaide, South Australia, 5000
A.W. Morrow Gastroenterology and Liver Centre
Camperdown, New South Wales, 2050
Lyell McEwin Hospital
Elizabeth Vale, South Australia, 5112
St Vincent's Hospital Melbourne - Gastroenterology Department
Fitzroy, Victoria, 3065
Austin Hospital
Heidelberg, Victoria, 3084
Nepean Hospital
Kingswood, New South Wales, 2747
Liverpool Hospital
Liverpool, New South Wales, 2170
Fiona Stanley Hospital - Hepatology
Murdoch, Western Australia, 6150
Sir Charles Gairdner Hospital - Hepatology Department
Nedlands, Western Australia, 6009
Griffith University Clinical Trial Unit
Southport, Queensland, 4222
Westmead Hospital - Storr Liver Centre
Westmead, New South Wales, 2145
Westmead Hospital
Westmead, New South Wales, 2145
Brazil11 sites
Fundação Pio XII
Barretos, São Paulo, 14780-070
Fundação Pio XII - Hospital de Amor de Barretos
Barretos, São Paulo, 14784-400
UPECLIN- Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
Botucatu, São Paulo, 18618-686
Hospital das Clínicas da Universidade Federal de Goiás
Goiânia, Goiás, 74605-020
Hospital de Clínicas de Porto Alegre_Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital Universitario Clementino Fraga Filho
Rio de Janeiro, 21941-617
Fundação Bahiana de Infectologia
Salvador, Estado de Bahia, 40110160
CIP Centro Integrado de Pesquisas do Hospital de Base
São José do Rio Preto, São Paulo, 15090-000
Assoc. Paulista para o Desenvolvimento da Medicina - UNIFESP
São Paulo, São Paulo, 04024-002
Departamento de Gastroenterologia - HCFMUSP
São Paulo, São Paulo, 05403-000
Rocco e Nazato Servicos Medicos LTDA
São Paulo, 04077-020
France11 sites
Centre Hospitalier Universitaire D'Angers-1
Angers, 49100
Centre Hospitalier Universitaire D'Angers
Angers, 49100
Ap-Hp-Hopital Beaujon
Clichy, 92110
Centre Hospitalier Universitaire de Lille-Hopital Claude Huriez
Lille, 59000
Hospices Civils de Lyon-Hopital de La Croix Rousse
Lyon, 69317
Centre Hospitalier Universitaire de Nice-Hopital de L'Archet
Nice, 06200
APHP-HOPITAL LA PITIE SALPETRIERE_Service Hépato-Gastro-Enterologie
Paris, 75013
Ap-Hp-Hopital Cochin
Paris, 75014
Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque
Pessac, 33600
Hospices Civils de Lyon-Hopital Lyon Sud
Pierre-Bénite, 69310
Les Hopitaux Universitaires de Strasbourg-Hopital Civil
Strasbourg, 67091
Israel10 sites
Carmel MC - Liver Unit
Haifa, 3434104
Carmel Medical Center Liver Unit
Haifa, 3434104
Shaare Zedek MC - Liver Unit
Jerusalem, 91031
Shaare Zedek Medical Center
Jerusalem, 91031
Hadassah Ein Karam MC - Liver Unit
Jerusalem, 91120
Western Galilee MC - Internal Medicine A
Nahariya, 2210001
Liver Institute, Rabin Medical Center, Beilinson Campuse
Petah Tikva, 49100
Rabin MC Beilinson - Liver Institute
Petah Tikva, 49100
Sheba MC - Liver Diseases Center
Ramat Gan, 52621
Sourasky MC - Liver Unit
Tel Aviv, 64239
Italy10 sites
Azieda Ospedaliero-Universitaria, Policlinico S. Orsola-Malp
Bologna, 40138
Azienda Ospedaliero-Universitaria Renato Dulbecco
Catanzaro, Cz, 88100
AOU Careggi Padiglione 16 San Luca, 3° piano
Florence, 50134
Azienda Ospedaliero Universitaria Ospedali Riuniti - Foggia
Foggia, 71122
Osp Magg Policlinico Centro Malattie metaboliche del Fegato
Milan, 20122
AOUP Giaccone Palermo
Palermo, Sicily, 90127
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Roma, 00168
Policlinico Università Campus Biomedico di Roma
Rome, 00128
IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo
San Giovanni Rotondo, Foggia, 71013
Città della salute e della scienza - university of Torino
Torino, 10126
Romania10 sites
Sana Monitoring SRL
Bucharest, 011025
Hightech Medical Services S.R.L.
Bucharest, 011053
Institutul Clinic Fundeni
Bucharest, 022328
Spitalul Universitar de Urgenta Bucuresti
Bucharest, 050098
Spitalul Clinic CF Cluj Napoca
Cluj-Napoca, 400015
Institutul Gastroenterologie-Hepatologie Cluj-Napoca
Cluj-Napoca, 400162
Gastroenterologie Spitalul Judetean Constanta
Constanța, 900591
SC Diamed Obesity SRL
Galati, 800291
Gastromedica
Iași, 700506
Spital Judetean De Urgenta Satu Mare
Satu Mare, 440055
Spain10 sites
Hospital Vall d'Hebron
Barcelona, 08035
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222
Complejo Hospitalario de Pontevedra - Hospital de Montecelo
Pontevedra, Galicia, 36004
Complejo Hospitalario de Pontevedra - Hospital de Montecelo
Pontevedra, 36004
Hospital Universitario Marqués de Valdecilla
Santander, 39008
Hospital Universitario Virgen del Rocío
Seville, 41013
Hospital General de Valencia
Valencia, 46014
Hospital Univ. y Politécnico La Fe
Valencia, 46026
Hospital Universitario y Politécnico La Fe
Valencia, 46026
Hospital Clínico de Valladolid
Valladolid, 47010
Taiwan10 sites
Ditmanson Medical Foundation Chia-Yi Christian Hospital
Chiayi City, 600
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
Taipei Tzu Chi Hospital
New Taipei City, 231
China Medical University Hospital
Taichung, 404
National Cheng Kung University Hospital
Tainan, 704
National Taiwan University Hospital_main
Taipei, 100
Taipei Mackay Memorial Hospital
Taipei, 104
Cathay General Hospital
Taipei, 106
Taipei Medical University Hospital
Taipei, 110
Taipei-Veterans General Hospital - Dept of Gastrointestinal
Taipei, 112
Argentina9 sites
DIM Clinica Privada
Buenos Aires, B1704ETD
Centro Médico Viamonte SRL
CABA, C1120AAC
Hospital Italiano Departamento Hepatologia
CABA, C1199ABH
Glenny Corp. S.A
CABA, C1430CKE
Centro de Investigaciones Metabólicas
Capital Federal, Buenos Aires, C1056ABI
Centro de Investigaciones Metabólicas
Capital Federal, C1056ABJ
Hospital Britanico de Buenos Aires
Ciudad de Buenos Aires, Buenos Aires, 1280
Hospital El Cruce
Florencio Varela, Buenos Aires, 1888
Hospital del Centenario
Rosario, Santa Fe, Santa Fe Province, S2002KDT
South Africa9 sites
Tiervlei Trial Centre
Cape Town, Western Cape, 7530
Dr Rajabally's Practice
Cape Town, Western Cape, 7800
Maxwell Centre
Durban, KwaZulu-Natal, 4001
Lenmed Shifa Private Hospital
Durban, KwaZulu-Natal, 4901
Chris Hani Baragwanath Hospital
Johannesburg, Gauteng, 2013
WITS Clinical Research
Johannesburg, Gauteng, 2193
Wits Health Consortium
Johannesburg, 2193
Lenasia Clinical Trial Centre
Lenasia, Gauteng, 1827
Phoenix Pharma
Port Elizabeth, Eastern Cape, 6001
South Korea9 sites
Kyungpook National University Hospital
Daegu, 41944
Yeungnam Univ. Medical Center
Daegu, 42415
Keimyung University Dongsan Hospital
Daegu, 42601
Wonju Severance Christian Hospital
Gangwon-do, 26426
Soon Chun Hyang University Hospital Bucheon
Gyeonggi-do, 14584
Severance Hospital, Yonsei University Health System
Seoul, 03722
Chung-Ang University Hospital
Seoul, 06973
SMG-SNU Boramae Medical Center
Seoul, 07061
Korea University Guro Hospital
Seoul, 08308
Greece8 sites
Gen Hospital of Athens Ippokrateio,B' Uni Clinic of Inte Med
Athens, 11527
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
Athens, 11527
General Hospital of Athens "LAIKO"
Goudi, Athens, 115 27
Univ Gen Hospital of Ioannina,Gastroenterology-Endoscopy Uni
Ioannina, 45500
Univ Gen Hospital Larisa, Cardiology Medicine Clinic
Larissa, 41110
"AHEPA" University Hospital of Thessaloniki
Thessaloniki, 54621
AHEPA General University Hospital
Thessaloniki, 54636
General Hospital of Thessaloniki "Ippokrateio"
Thessaloniki, 54642
Mexico8 sites
Centro de Investigacion Clinica del Pacifico, S.A. de C.V.
Acapulco de Juárez, Guerrero, 39670
Hospital Angeles de Culiacan
Culiacán, Sinaloa, 80020
Centro de Investigación Médico Biológica y Terapia
Guadalajara, Jalisco, 44130
Medical Care and Research S. A de C.V
Mérida, Yucatán, 97070
Centro de Investigación y Gastroenterología_ Hospital Angeles Universidad
México, 03330
Centro de Investigación y Gastroenterología, S.C.
Mexico City, México, D.F., 06700
Investigaciones Médicas Cisneros, S.C.
Monterrey, Nuevo León, 64000
Servicios de Oncologia Medica Integral S.A de C.V (ONCARE)
San Pedro Garza García, Nuevo León, 66220
Croatia7 sites
Klinicki bolnicki centar Osijek_Endocrinology
Osijek, 31 000
Klinicki bolnicki centar Osijek
Osijek, 31 000
KBC Rijeka, Zavod za gastroenterologiju
Rijeka, 51000
KBC Split/ Firule/ Gastroenterologija
Split, 21000
KBC Split_Gastroenterology
Split, 21000
KB Dubrava, Zavod za gastroenterologiju
Zagreb, 10000
Klinički bolnički centar Zagreb, Zavod za gastroenterologiju
Zagreb, 10000
Poland7 sites
Gizinscy Centrum Medyczne
Bydgoszcz, 85-676
ID Clinic Arkadiusz Pisula
Myslowice, Lesser Poland Voivodeship, 41-400
Ko-Med Centra Kliniczne Staszow
Staszów, Świętokrzyskie Voivodeship, 28-200
Velocity Nova Sp. z o.o.
Staszów, Świętokrzyskie Voivodeship, 28-200
Bodyclinic Sp. z o.o. sp.k.
Warsaw, 03-712
Centrum Badan Klinicznych
Wroclaw, 51-162
FutureMeds Sp. z o.o.
Wroclaw, 53-673
Belgium6 sites
CUB Hôpital Erasme_Brussels_0
Brussels, 1070
Cliniques Universitaires Saint-Luc - Serv. Hépato-gastroentérology
Brussels, 1200
UZA
Edegem, 2650
Ziekenhuis Oost-Limburg AV - Gastro
Genk, 3600
AZ Maria Middelares - Gent - Gastro-Enterology
Ghent, 9000
UZ Gent - Department Gastro-enterology
Ghent, 9000
Austria5 sites
Klin.Abt. f. Gastroenterologie u. Hepatologie
Graz, 8036
Fließer-Görzer [Ordination]
Saint Stefan, 8511
LKH Salzburg Universitätsklinikum
Salzburg, 5020
Klinik Landstraße
Vienna, 1030
Klinikum Wels-Grieskirchen
Wels, 4600
Singapore5 sites
National University Hospital Singapore_Tahir Building
Singapore, 119228
National University Hospital_Tahir Building
Singapore, 119228
Singapore General Hospital
Singapore, 169608
Changi General Hospital
Singapore, 529889
Changi General Hospital
Singapore, 529905
Slovakia5 sites
Nemocnica akademika L. Derera, UNB
Bratislava, 833 05
MEDISPEKTRUM s.r.o.
Bratislava, 851 01
II. Interna klinika, Univerzitna nemocnica L. Pasteura Kosice
Košice, 040 11
Hepatobiliarne centrum - Michalovce
Michalovce, 071 01
JAL s.r.o.
Trnava, 91701
Switzerland5 sites
Universitätsklinik für Viszerale Chirurgie und Medizin
Bern, 3010
Hôpitaux Universitaires de Genève
Geneva, 1211
Kantonsspital Olten
Olten, 4600
Kantonsspital St. Gallen
Sankt Gallen, 9007
USZ Klinik für Gastroenterologie und Hepatologie
Zurich, 8091
Denmark4 sites
Aarhus Universitetshospital Skejby Mave-Tarm
Aarhus N, 8200
Hvidovre Hospital - Gastroenheden
Hvidovre, 2650
Bispebjerg Hospital - Abdominal Center K, Research Unit
København NV, 2400
Odense University Hospital - FLASH - Centre for Liver Research
Odense C, 5000
Malaysia4 sites
Hospital Selayang
Batu Caves, 68100
Hospital Universiti Sains Malaysia
Kota Bharu, Kelantan, 16150
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, 59100
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, 59100
Netherlands4 sites
Noordwest Ziekenhuisgroep
Alkmaar, 1815 JD
AmsterdamUMC AMC
Amsterdam, 1105 AZ
Leids Universitair Medisch Centrum
Leiden, 2333 ZA
Franciscus Gasthuis en Vlietland
Rotterdam, 3045 PM
Serbia4 sites
Clinic for gastroenterology and hepatology
Belgrade, 11000
Endocrinology, Diabetes and Metabolism Diseases Clinic
Belgrade, 11000
Clinical-hospital centre Zvezdara
Belgrade, 11020
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
Novi Sad, Vojvodina, 21000
Czechia3 sites
Krajská nemocice Liberec, a.s
Liberec, 460 01
Researchsite s.r.o.
Pilsen, 301 00
Vseobecna Fakultni nemocnice v Praze
Prague, 128 08
Norway3 sites
Bærum sykehus - Vestre Viken HF
Gjettum, 1346
Bærum sykehus
Gjettum, 1346
Oslo universitetssykehus, Ullevål
Oslo, 0450
Ireland2 sites
Hepatology St James's
Dublin, D08 NHY1
Beaumont Hospital Hepatology Dept
Dublin, D09V2N0
About this study
Official title: The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
Read more
Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.
The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.
Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
- Conditions
- Non-alcoholic Steatohepatitis
- Being tested
- Semaglutide, Placebo
- Medical subject headings
- Non-alcoholic Fatty Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SemaglutideDrug
Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
PlaceboDrug
Placebo administrated subcutaneously (under the skin) once weekly.
| Study group | Role | What they receive |
|---|---|---|
| Semaglutide OW (once weekly ) | Experimental | Semaglutide administrated subcutaneously once weekly Receives: Drug: Semaglutide |
| Placebo | Placebo comparator | Placebo administrated subcutaneously once weekly Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Part 2: Cirrhosis-free survival (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 240
Secondary outcomes (35)
Change in body weight
Percentage
Measured: From randomisation (week 0) to week 72
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Change in SF-36 (Short Form 36) Bodily Pain
Score points
Measured: From randomisation (week 0) to week 72
Change in body weight
Percentage
Measured: From randomisation (week 0) to week 240
Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Change in histology-assessed liver collagen proportionate area
Ratio to baseline
Measured: From randomisation (week 0) to week 72
Worsening in steatohepatitis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Improvement in histology-assessed ballooning (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Improvement in histology-assessed inflammation (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Improvement in histology-assessed steatosis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
NASH resolution (ballooning of 0, inflammation of 0-1) and above or equal to 2point NAS reduction with no worsening of fibrosis
Count of subject
Measured: From randomisation (week 0) to week 72
Progression of liver fibrosis in patients with F2 at baseline (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 72
Progression of liver fibrosis
Count of subject
Measured: From randomisation (week 0) to week 72
Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 240
Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 240
Absence of histological evidence of NASH (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 240
Changes in liver stiffness values assessed by transient elastography (FibroScan®)
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in ELF (Enhanced Liver Fibrosis) score
Logarithm
Measured: From randomisation (week 0) to week 72 and week 240
Change in ALT (alanine aminotransferase)
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in AST (aspartate aminotransferase)
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)
Absolute change
Measured: From randomisation (week 0) to week 72 and week 240
Change in FAST (FibroScan-AST) score
Probability (absolute change)
Measured: From randomisation (week 0) to week 72 and week 240
Change in Pro-C3 (pro-peptide of type III collagen)
Logarithm
Measured: From randomisation (week 0) to week 72 and week 240
Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in HbA1c (glycated haemoglobin)
Percentage-points (absolute change)
Measured: From randomisation (week 0) to week 72 and week 240
Change in triglyceride
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in free fatty acids
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in LDL (low-density lipoprotein) cholesterol
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Change in HDL (High density lipoprotein ) cholesterol
Ratio to baseline
Measured: From randomisation (week 0) to week 72 and week 240
Time to first MACE(Major Adverse Cardiovascular event ) (composite endpoint)
Days
Measured: From randomisation (week 0) to week 240
Major cardio-hepatic event-free survival (Yes/No)
Count of subject
Measured: From randomisation (week 0) to week 240
Changes in SF-36 (Short Form 36 v2.0 acute ) Physical Component Summary
Score points
Measured: From randomisation (week 0) to week 72 and week 240
Changes in SF-36 Mental Component Summary
Score points
Measured: From randomisation (week 0) to week 72 and week 240
Change in SF-36 Bodily Pain
Score points
Measured: From randomisation (week 0) to week 240
Changes in NASH-CHECK Abdominal Pain
Score points
Measured: From randomisation (week 0) to week 72 and week 240
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2021
- Study start1 Apr 2021
- Primary completion25 Apr 2029 (estimated)
- Study completion25 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Non-alcoholic SteatohepatitisStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,205 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04822181
- Sponsor's protocol ID
- NN9931-4553
- Other IDs
- U1111-1244-3678, 2019-004594-44, jRCT2031210033, 2019
- Acronym
- ESSENCE
- Status last verified
- Oct 2026
- First submitted
- 26 Mar 2021
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Publications
Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D, Bugianesi E, Rinella ME, Roden M, Ratziu V. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1525-1533. doi: 10.1111/apt.18331. Epub 2024 Oct 16.
PubMed 39412509Nakajima A, Okanoue T, Hiasa Y, Takahashi H, Opuni K, Kosaka N, Nishida T, Sanyal AJ. Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial. J Gastroenterol. 2026 Aug 28. doi: 10.1007/s00535-026-02507-0. Online ahead of print.
PubMed 42663669Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
PubMed 40305708Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists. Hepatol Commun. 2024 Oct 10;8(11):e0561. doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1.
PubMed 39392766Rowe IA, Allen AM. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease. Hepatology. 2023 Jun 1;77(6):1843-1845. doi: 10.1097/HEP.0000000000000327. Epub 2023 Feb 6. No abstract available.
PubMed 36738088
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
- ClinicalTrials.gov ID
- NCT04822181
- Acronym / sponsor ID
- ESSENCE / NN9931-4553
- Conditions
- Non-alcoholic Steatohepatitis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,205 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 25 Apr 2029 (estimated)
- Study completion
- 25 Apr 2029 (estimated)
- First posted
- 30 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.
The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.
Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Semaglutide OW (once weekly ) | Experimental | Drug: SemaglutideSemaglutide administrated subcutaneously once weekly |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo administrated subcutaneously once weekly |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age above or equal to 18 years at the time of signing informed consent.
- Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1).
- Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy.
- A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy.
Key exclusion criteria (7 listed)
- Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)
- Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
- Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.
- Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
- Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SemaglutideSemaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose. | Drug | Semaglutide OW (once weekly ) |
| PlaceboPlacebo administrated subcutaneously (under the skin) once weekly. | Drug | Placebo |
Primary outcome
Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Time frame: From randomisation (week 0) to week 72
Count of subject
Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Time frame: From randomisation (week 0) to week 72
Count of subject
Part 2: Cirrhosis-free survival (Yes/No)
Time frame: From randomisation (week 0) to week 240
Count of subject
35 secondary outcomes
Change in body weight
Time frame: From randomisation (week 0) to week 72
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)
Time frame: From randomisation (week 0) to week 72
Change in SF-36 (Short Form 36) Bodily Pain
Time frame: From randomisation (week 0) to week 72
Change in body weight
Time frame: From randomisation (week 0) to week 240
Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)
Time frame: From randomisation (week 0) to week 72
Change in histology-assessed liver collagen proportionate area
Time frame: From randomisation (week 0) to week 72
Worsening in steatohepatitis (Yes/No)
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed ballooning (Yes/No)
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed inflammation (Yes/No)
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed steatosis (Yes/No)
Time frame: From randomisation (week 0) to week 72
NASH resolution (ballooning of 0, inflammation of 0-1) and above or equal to 2point NAS reduction with no worsening of fibrosis
Time frame: From randomisation (week 0) to week 72
Progression of liver fibrosis in patients with F2 at baseline (Yes/No)
Time frame: From randomisation (week 0) to week 72
Progression of liver fibrosis
Time frame: From randomisation (week 0) to week 72
Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Time frame: From randomisation (week 0) to week 240
Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Time frame: From randomisation (week 0) to week 240
Absence of histological evidence of NASH (Yes/No)
Time frame: From randomisation (week 0) to week 240
Changes in liver stiffness values assessed by transient elastography (FibroScan®)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in ELF (Enhanced Liver Fibrosis) score
Time frame: From randomisation (week 0) to week 72 and week 240
Change in ALT (alanine aminotransferase)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in AST (aspartate aminotransferase)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in FAST (FibroScan-AST) score
Time frame: From randomisation (week 0) to week 72 and week 240
Change in Pro-C3 (pro-peptide of type III collagen)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in HbA1c (glycated haemoglobin)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in triglyceride
Time frame: From randomisation (week 0) to week 72 and week 240
Change in free fatty acids
Time frame: From randomisation (week 0) to week 72 and week 240
Change in LDL (low-density lipoprotein) cholesterol
Time frame: From randomisation (week 0) to week 72 and week 240
Change in HDL (High density lipoprotein ) cholesterol
Time frame: From randomisation (week 0) to week 72 and week 240
Time to first MACE(Major Adverse Cardiovascular event ) (composite endpoint)
Time frame: From randomisation (week 0) to week 240
Major cardio-hepatic event-free survival (Yes/No)
Time frame: From randomisation (week 0) to week 240
Changes in SF-36 (Short Form 36 v2.0 acute ) Physical Component Summary
Time frame: From randomisation (week 0) to week 72 and week 240
Changes in SF-36 Mental Component Summary
Time frame: From randomisation (week 0) to week 72 and week 240
Change in SF-36 Bodily Pain
Time frame: From randomisation (week 0) to week 240
Changes in NASH-CHECK Abdominal Pain
Time frame: From randomisation (week 0) to week 72 and week 240
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Results publication: PubMed 39412509Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Ostergaard L, Vanni D, Bugianesi E, Rinella ME, Roden M, Ratziu V. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1525-1533. doi: 10.1111/apt.18331. Epub 2024 Oct 16.
- Derived from this study: PubMed 42663669Nakajima A, Okanoue T, Hiasa Y, Takahashi H, Opuni K, Kosaka N, Nishida T, Sanyal AJ. Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial. J Gastroenterol. 2026 Aug 28. doi: 10.1007/s00535-026-02507-0. Online ahead of print.
- Derived from this study: PubMed 40305708Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
- Derived from this study: PubMed 39392766Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists. Hepatol Commun. 2024 Oct 10;8(11):e0561. doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1.
- Derived from this study: PubMed 36738088Rowe IA, Allen AM. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease. Hepatology. 2023 Jun 1;77(6):1843-1845. doi: 10.1097/HEP.0000000000000327. Epub 2023 Feb 6. No abstract available.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Non-alcoholic Steatohepatitis
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NASH With Fibrosis, MASH With Fibrosis
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
558 sites in 39 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Semaglutide in people with Non-alcoholic Steatohepatitis, run by Novo Nordisk A/S at 558 sites in 39 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 558 sites in United States, Japan, China, United Kingdom, India and 34 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No) (time frame: From randomisation (week 0) to week 72). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04822181, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.